What is the common examiner trap about Science & Tech in UPSC exams?

Students may confuse 'carbapenem resistance' with 'antibiotic resistance' in general, or assume that the study's findings represent the entire Indian population. The article explicitly states that the data comes from tertiary-care hospitals and should not be interpreted as community-level resistance. Also, the cost data is only for antibiotics under Jan Aushadhi scheme, not total treatment cost. Examiners may ask for the exact mortality range for bloodstream infections (39-51%) or the relative risk (1.16-1.43).

What should UPSC aspirants remember about Science & Tech for Prelims?

1. Target this Data: 61% Gram-negative infections were carbapenem-resistant; mortality 39-51% in bloodstream infections; relative risk of death 1.16-1.43; antibiotic cost 1.1-2 times higher. 2. Target this Nodal Body: Indian Council of Medical Research (ICMR) – conducted the study through its antimicrobial resistance surveillance network. 3. Target this Legal Point: No specific act mentioned, but the study emphasized the need for antimicrobial stewardship and infection prevention under healthcare guidelines.

Science_TechSocial_Issues

Take AI Challenge ▸

News 18 of 25

ICMR Study: 61% Gram-Negative Infections Carbapenem-Resistant; Mortality 39-51%

Q: Which organization conducted the study on carbapenem-resistant Gram-negative infections in Indian hospitals mentioned in the article?

Indian Council of Medical Research (ICMR), The article specifies that the researchers were part of the ICMR's antimicrobial resistance surveillance network. The study was conducted by ICMR across 20 tertiary-care hospitals. WHO, NCDC, or Ministry were not directly involved in this study.

Q: Consider the following statements regarding the ICMR study on carbapenem resistance: 1. The study found that the relative risk of death from carbapenem-resistant infections ranged from 1.16 to 1.43. 2. The study concluded that antibiotic overuse is the sole cause of antimicrobial resistance in India. 3. More than 85% of bloodstream infections in the study were classified as healthcare-associated. Which of the statements given above is/are correct?

Both 1 and 3, Statement 1 is correct: the article mentions relative risk of death 1.16-1.43 across the four bacteria. Statement 2 is incorrect: the article explicitly says AMR is a complex interaction of antibiotic pressure, infection control, transmission, and diagnostics, not just overuse. Statement 3 is correct: >85% of bloodstream infections were healthcare-associated. Hence option C is correct.

Q: According to the ICMR study, what was the mortality rate for bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii?

51%, The article states: 'mortality among bloodstream infections ranged from about 39% in resistant E. coli to 51% in resistant A. baumannii.' Therefore, 51% is the correct figure for A. baumannii. The other options are distractors: 39% is for E. coli, 45% and 57% are not mentioned.

Q: What is the primary reason the study authors emphasize that antimicrobial resistance cannot be solved by discovering new antibiotics alone?

Prevention, diagnostics, and stewardship are equally critical to preserve existing and new antibiotics, The article concludes with the message: 'AMR cannot be solved by discovering another antibiotic every time an old one fails. We have to prevent infections, diagnose them early and preserve the antibiotics we still have.' This highlights the need for a multi-pronged approach beyond just drug discovery.

Science & Tech Social IssuesCORE

Target:UPSC GS-IIIMPSCSSC GATeachingPrelims HighMains MediumStatic GK Link

02 Sept 2026

~2 min

Source: Indian Express

Key Data:1,59,336 hospitalised patients61% carbapenem-resistantRelative risk 1.16-1.43Mortality 39-51% bloodstream infectionsAntibiotic cost 1.1-2 times higher85% healthcare-associated infections

Bodies:ICMR

Practice MCQs from today's news ▸

~2 min · Quick mode

What This Article Covers

1.ICMR study of 1,59,336 hospitalised patients across 20 tertiary-care hospitals (April 2022 – April 2025) found 61% of Gram-negative infections were carbapenem-resistant.

2.Carbapenem resistance increased relative risk of death 1.16-1.43 times across four major pathogens (E. coli, K. pneumoniae, A. baumannii, P. aeruginosa).

3.Bloodstream infection mortality ranged from 39% (resistant E. coli) to 51% (resistant A. baumannii); antibiotic cost up to 2x higher under Jan Aushadhi scheme.

The Big Picture

Prelims · HighMains · Medium

A large ICMR study across 20 Indian hospitals (2022-2025) reveals that carbapenem-resistant Gram-negative infections cause significantly higher mortality (39-51% in bloodstream infections) and cost 1.1-2 times more to treat. The study stresses that antimicrobial resistance is a complex interplay of healthcare transmission, antibiotic pressure, and diagnostic gaps, not just antibiotic overuse.

Exam Lens

Quick Exam Facts From News

Study PeriodApril 2022 – April 2025

Sample Size1,59,336 hospitalised patients

Resistance Rate61% Gram-negative infections were carbapenem-resistant

Relative Risk of Death1.16 – 1.43 across four pathogens

Bloodstream Infection Mortality39% (E. coli) to 51% (A. baumannii)

Antibiotic Cost Increase1.1 – 2 times higher (Jan Aushadhi scheme prices)

1-Minute Revision

›Study Period: April 2022 – April 2025
›Sample Size: 1,59,336 hospitalised patients
›Target this Data: 61% Gram-negative infections were carbapenem-resistant; mortality 39-51% in bloodstream infections; relative risk of death 1.16-1.43; antibiotic cost 1.1-2 times higher.
›Target this Nodal Body: Indian Council of Medical Research (ICMR) – conducted the study through its antimicrobial resistance surveillance network.
›Target this Legal Point: No specific act mentioned, but the study emphasized the need for antimicrobial stewardship and infection prevention under healthcare guidelines.

Mastered this topic? Test your knowledge with a full MCQ quiz.

Practice exam-style questions, track your score, and strengthen your recall.

News Snapshot

🦠

Gram-Negative Bacteria

E. coli, K. pneumoniae, A. baumannii, P. aeruginosa – major hospital pathogens with high carbapenem resistance.

💊

Carbapenem Resistance

Resistance to last-resort antibiotics leads to limited treatment options, higher mortality and costs.

🏥

Healthcare-Associated Infections

Over 85% of bloodstream infections were healthcare-associated, highlighting infection prevention gaps.

Detailed Analysis & Strategic Depth

Context / Background

Antimicrobial resistance (AMR) is a global health crisis. In India, carbapenem-resistant Gram-negative infections are a growing threat due to overuse of antibiotics, poor infection control, and lack of rapid diagnostics. The ICMR's AMR surveillance network conducted this large study to quantify the real-world impact of carbapenem resistance on patient outcomes and costs.

Core Analysis & Implications

The study found that carbapenem resistance was consistently associated with higher mortality across all four major Gram-negative bacteria, with relative risk ranging 1.16-1.43. Importantly, 61% of Gram-negative infections in these tertiary-care hospitals were carbapenem-resistant. The study also highlighted that antibiotic cost alone was 1.1-2 times higher; actual economic burden including ICU, diagnostics, and supportive care is likely much greater. The finding that >85% of bloodstream infections were healthcare-associated shifts focus from antibiotic overuse alone to infection prevention.

Future Outlook / Way Forward

The authors recommend: (1) move from isolate-based AMR surveillance to integrated surveillance linking lab results with patient outcomes; (2) faster, accurate diagnostics to identify resistance early; (3) antimicrobial stewardship as routine clinical practice; (4) infection prevention as a priority equal to antibiotic prescribing; (5) responsible access to new antimicrobials with stewardship. The larger message is that AMR cannot be solved by discovering new antibiotics alone—prevention, diagnostics, and stewardship are crucial.

Key Facts at a Glance

Study PeriodApril 2022 – April 2025

Sample Size1,59,336 hospitalised patients

Resistance Rate61% Gram-negative infections were carbapenem-resistant

Relative Risk of Death1.16 – 1.43 across four pathogens

Bloodstream Infection Mortality39% (E. coli) to 51% (A. baumannii)

Antibiotic Cost Increase1.1 – 2 times higher (Jan Aushadhi scheme prices)

You've read the full analysis. Now test your understanding.

Practice exam-style questions based on this article.

Q1Static LinkageEasyUPSC, SSC, Banking, State PSC

Which organization conducted the study on carbapenem-resistant Gram-negative infections in Indian hospitals mentioned in the article?

Q2Statement-basedHardUPSC, SSC, State PSC

Consider the following statements regarding the ICMR study on carbapenem resistance:

1. The study found that the relative risk of death from carbapenem-resistant infections ranged from 1.16 to 1.43.

2. The study concluded that antibiotic overuse is the sole cause of antimicrobial resistance in India.

3. More than 85% of bloodstream infections in the study were classified as healthcare-associated.

Which of the statements given above is/are correct?

Q3Data-centricMediumUPSC, Banking, SSC

According to the ICMR study, what was the mortality rate for bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii?

Q4Application/ImpactMediumUPSC, SSC, Teaching

What is the primary reason the study authors emphasize that antimicrobial resistance cannot be solved by discovering new antibiotics alone?

All 25 MCQs ▸

Read original article from Indian Express

You finished this topic

Practice 3 MCQs from this news Next Article

Explore Related Topics

Science & TechView Topic MCQs →Social IssuesView Topic MCQs →

PreviousPrivate Players Seek Green Energy Status for Nuclear Power; 100 GWe, $228 Bn Target by 2047 Next India's Data Centre Boom: $200B Investment, 6.5 GW Capacity by 2030 Strains Power & Water

Related Current Affairs

Science & Tech Current Affairs

Proposed Patient Data Collective (PDC) Model for Rare Diseases in India Inspired by Amul Cooperative

A new proposal suggests creating a Patient Data Collective (PDC) for rare diseases in India, modeled on the Amul dairy cooperative. This collective would pool patient data to accelerate drug discovery and clinical trials, addressing the challenge of small patient populations for rare diseases.

Science & Tech Current Affairs

KARS-Net 2025 Report: 73% ESBL E. coli, 43% Carbapenem-Resistant Klebsiella in Kerala

Kerala's 2025 antimicrobial resistance (AMR) surveillance data reveals a critical public health crisis: drug-resistant bacteria are now the norm, not the exception, in both hospital and community settings. With E. coli showing 73% ESBL positivity and Klebsiella 43% carbapenem resistance, this report signals an urgent need for antibiotic stewardship and policy intervention.

Social Issues Current Affairs

VP Launches India Valve Registry for Heart Valve Disease Research; TN Reports 2,590 Valve Replacements in 20 Months

The Vice-President launched the India Valve Registry, a first-of-its-kind clinician-led platform to collect real-world data on valvular heart disease and interventions in India. The registry will generate India-specific evidence to improve patient care, while Tamil Nadu's CMCHIS data reveals 2,590 valve replacements in 20 months, highlighting the burden of rheumatic heart disease and the success of state-led healthcare.

Science & Tech Current Affairs

Candida auris Shows 90% Azole Resistance; Study Reveals Gene Duplication & Eagle Effect Challenging Antifungals

Fungal infections are rising due to global warming, with Candida auris emerging as a multidrug-resistant threat (30-40% mortality). New research from JNCASB and collaborators reveals that C. auris uses gene duplication (Erg11) and mutations (Fks1) to resist antifungals, and also exhibits the 'Eagle effect' where high drug doses paradoxically trigger compensatory chitin production, making the pathogen survive. This signals the end of the chemical arms race approach and calls for combination therapies and revised susceptibility testing limits.

Polity Current Affairs

MeitY Summons Meta Global Team Over Algorithmic Bias; Parliamentary Panel to Question

Government summons Meta's global team to clarify algorithmic bias and role in public order after MeitY rejects technical glitch explanation. Parliamentary panel will also question the company. This highlights growing regulatory scrutiny on social media algorithms and their societal impact.

Science & Tech Current Affairs

India Gets First Disease-Modifying Alzheimer's Drug Leqembi After CDSCO Nod

Eisai's Leqembi (lecanemab), India's first disease-modifying therapy for early Alzheimer's, has been launched after CDSCO approval. This marks a shift from symptomatic to disease-modifying treatment, but challenges of early diagnosis, biomarker infrastructure, and affordability remain significant.

Social Issues Current Affairs

NOTTO Reports 20,000+ Transplants in 2025, Launches Portal and Swap Guidelines

NOTTO released 2025 data showing over 20,000 transplants, persistent gender disparity in organ donation (68% female donors vs 78% male recipients), and launched a new digital portal to enhance transparency. New swap transplantation guidelines aim to expand matching beyond single hospitals, but legal recognition under THOTA is still pending.

Science & Tech Current Affairs

IARC Classifies Three WHO Essential Medicines as Group 1 Carcinogens: Hydrochlorothiazide, Voriconazole, Tacrolimus

IARC, the WHO cancer research agency, has classified three widely used drugs—hydrochlorothiazide, voriconazole, and tacrolimus—as Group 1 carcinogens. Despite this, experts stress that patients should not stop treatment as the benefits for hypertension, fungal infections, and organ transplant rejection far outweigh the cancer risk. The drugs are on the WHO Model List of Essential Medicines and are commonly prescribed in India.

Start Today's Quiz(25 Qs)

Take Today's Quiz

25 Qs • 5-7 Mins

ICMR Study: 61% Gram-Negative Infections Carbapenem-Resistant; Mortality 39-51%

Exam Lens

Quick Exam Facts From News

1-Minute Revision

News Snapshot

Gram-Negative Bacteria

Carbapenem Resistance

Healthcare-Associated Infections

Detailed Analysis & Strategic Depth

Context / Background

Core Analysis & Implications

Future Outlook / Way Forward

Prelims Flashpoints

Key Facts at a Glance